In the Salford Lung Study, an open label, effectiveness RCT
comparing Relvar with usual care in over 4,000 patients, the
most commonly used ICS/LABAs in the ITT population were3:
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.